Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Survey aims to uncover hidden struggles of rare artery disease

NCT ID NCT07351422

First seen Jan 24, 2026 · Last updated Jun 22, 2026 · Updated 18 times

Summary

This study uses two online questionnaires to learn about the experiences of people with Takayasu arteritis and how doctors manage the condition. About 50 patients and an unspecified number of physicians in the UK will share their views on symptoms, treatment priorities, and unmet needs. The goal is to improve understanding and care for this rare inflammatory artery disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TAKAYASU ARTERITIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of Edinburgh

    RECRUITING

    Edinburgh, United Kingdom

    Contact Phone: •••-•••-•••• Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this could highlight gaps in care and guide better management strategies for Takayasu arteritis.

What could go wrong

This is an observational survey study, not a treatment trial. It collects opinions and may not lead to direct changes in care.

Conditions

The condition(s) this trial relates to.

Takayasu arteritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.